# Cancer Biopsy Market

> Cancer Biopsy Market Research Report: Size, Share, Trend Analysis By Types (Surgical Biopsy, Needle Biopsy, Endoscopic Biopsy, Liquid Biopsy), By Applications (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer), By Technique (Core Needle Biopsy, Fine-Needle Aspiration, Excisional Biopsy, Incisional Biopsy), By End Users (Hospitals, Diagnostic Laboratories, Cancer Research Institutes) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.49%
- **2024:** $ 11.11 Billion
- **2025:** $ 11.72 Billion
- **2035:** $ 20 Billion
- **Key Players:** Roche(CH), Thermo Fisher Scientific (US), Abbott Laboratories (US), Becton Dickinson and Company (US), Hologic (US), Siemens Healthineers (DE), Philips (NL), Agilent Technologies (US), Exact Sciences Corporation (US)

**Report ID:** MRFR/HC/40644-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/cancer-biopsy-market-42309

---

## Market Summary

## **Cancer Biopsy Market Overview**

As per MRFR analysis, the Cancer Biopsy Market Size was estimated at 10.53 (USD Billion) in 2023. The Cancer Biopsy Market Industry is expected to grow from 11.1(USD Billion) in 2024 to 20.0 (USD Billion) by 2035. The Cancer Biopsy Market CAGR (growth rate) is expected to be around 5.49% during the forecast period (2025 - 2035).

### **Key Cancer Biopsy Market Trends Highlighted**

The Global Cancer Biopsy Market is driven by a growing prevalence of cancer worldwide, prompting an increased demand for effective diagnostic tools. Advancements in technology, such as liquid biopsy and image-guided biopsy techniques, are enhancing the accuracy and safety of cancer diagnosis, making it easier for physicians to make informed decisions. The rising awareness about early cancer detection and personalized medicine has further fueled market growth as more patients seek out innovative biopsy options that provide better insights into their cancer type and treatment plans.

Opportunities exist in expanding markets, particularly in developing regions where access to advanced healthcare technologies is limited.With the improvement of health frameworks in these regions, there is also an opportunity for growth in the utilization of cancer biopsy surgeries. Moreover, partnerships between research institutions and biotechnology companies may lead to the creation of advanced biopsy procedures such as ‘no-touch’ and ‘biomarker’ –based techniques. Such investments and partnerships have the potential to substantially improve market presence.

These recent patterns point towards higher adoption of liquid biopsy techniques due to their less invasive nature, as well as the real-time information they provide about the tumor's activity. Reported information suggests an emphasis on diverse treatment plans and targeted strategies, making specific fibroscopies necessary for the custom therapies based on the patient.The integration of artificial intelligence and machine learning in analyzing biopsy results is also gaining traction, streamlining the diagnostic process and improving accuracy. Additionally, regulatory changes aimed at expediting the approval process for new diagnostic tools are fostering a more conducive environment for innovation.

Overall, the landscape of the Global Cancer Biopsy Market is rapidly evolving, with continuous advancements and a heightened focus on patient-centric solutions.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Cancer Biopsy Market Drivers**

### **Increasing Incidence of Cancer**

The Global Cancer Biopsy Market Industry is experiencing significant growth due to the rising incidence of cancer worldwide. As the global population ages and lifestyle-related risk factors continue to escalate, the number of cancer cases has surged. This increase presents a pressing demand for accurate diagnosis and timely intervention, thereby driving the need for effective biopsy procedures. The advancement in biopsy techniques, such as liquid biopsies and image-guided biopsies, has further spurred interest in cancer diagnostics.As healthcare systems aim to improve patient outcomes, there is an increasing emphasis on early detection, which is crucial for successful cancer treatment.

As a consequence, healthcare providers are investing in infrastructure and technology to enhance biopsy procedures.

This trend reflects a broader shift in the healthcare sector towards precision medicine and personalized care, where understanding the molecular characteristics of tumors through biopsies is paramount.This focus on tailored therapies necessitates robust biopsy solutions, thereby propelling growth in the Global Cancer Biopsy Market Industry. Furthermore, public awareness campaigns highlighting the importance of early cancer detection resonate with patients and healthcare providers alike, leading to increased demand for biopsy as an essential diagnostic tool.

As stakeholders recognize the role of biopsies in enhancing treatment efficiency and patient satisfaction, the market outlook remains promising, contributing to a significant surge in the industry's valuation.

### **Technological Advancements in Biopsy Procedures**

The Global Cancer Biopsy Market Industry is being significantly driven by technological advancements in biopsy procedures. Innovations such as minimally invasive techniques, improved imaging technologies, and the development of more sophisticated biopsy tools have revolutionized the field. These advancements not only enhance the accuracy and safety of biopsies but also reduce patient discomfort and recovery time.

For instance, image-guided biopsies allow for precise targeting of tumors, ensuring that samples are taken from the most relevant areas for accurate diagnosis.Additionally, liquid biopsy techniques enable the detection of cancer-related genetic material from blood samples, providing a less invasive alternative to traditional methods. Such innovations continue to attract investment and research, further propelling the growth of the Global Cancer Biopsy Market Industry.

### **Growing Demand for Early Cancer Detection**

There is an escalating global demand for early cancer detection, which significantly influences the Global Cancer Biopsy Market Industry. Early-stage diagnosis enables timely treatment, ultimately improving patient outcomes and survival rates. As awareness of cancer risks increases and the effectiveness of early detection campaigns spreads, more individuals are opting for routine screenings that often involve biopsy procedures. The healthcare sector is thus placing a higher priority on diagnostic accuracy and the deployment of advanced biopsy techniques.The rising focus on preventive healthcare fuels this demand, with public health initiatives actively encouraging regular cancer screening and monitoring.

## **Cancer Biopsy Market Segment Insights**

### **Cancer Biopsy Market Type Insights**

The Global Cancer Biopsy Market showed promising growth and diversification across its various types, reflecting an increasing demand for effective cancer detection methods. By 2024, the market for cancer biopsies will be valued at 11.1 USD Billion, with a notable breakdown into distinct biopsies based on their procedures. Surgical Biopsy is projected to hold a significant position, valued at 3.2 USD Billion in 2024, and expected to increase to 6.0 USD Billion by 2035.

This method is crucial for obtaining tissue samples for histological analysis, providing comprehensive insights into tumor characteristics and aiding treatment decisions. In addition, Needle Biopsy takes a prominent share within the market, valued at 4.0 USD Billion in 2024 and projected to reach 7.5 USD Billion by 2035.

The non-invasive nature and higher accuracy of needle biopsies make them a preferred choice among healthcare providers, contributing to their growth and dominance in the Global Cancer Biopsy Market revenue.Endoscopic Biopsy also plays a relevant role, valued at 2.0 USD Billion in 2024, and is expected to grow to 3.5 USD Billion in 2035.

This type is especially significant for gastrointestinal tumors, allowing access to hard-to-reach areas while simultaneously providing therapeutic options, thus enhancing patient outcomes and healthcare efficiency. Finally, Liquid Biopsy, although currently the smallest segment at 1.9 USD Billion in 2024, is anticipated to expand to 3.0 USD Billion by 2035. The rise of liquid biopsy is noteworthy due to its minimally invasive approach and capacity to capture circulating tumor DNA, making it an attractive option for cancer screening and monitoring.

This method offers valuable insights with less risk and discomfort to patients, thus indicating a shift in preference towards non-invasive techniques in the industry.

Together, these types not only illustrate the diversity of the Global Cancer Biopsy Market segmentation but also highlight trends such as the growing inclination towards minimally invasive procedures and precision medicine. The market growth is further stimulated by increasing cancer incidences and advancements in biopsy technologies, creating a wealth of opportunity for industry stakeholders. Growth drivers also include the rising awareness of early diagnosis, the expansion of healthcare infrastructure, and continuous innovations in biopsy techniques. Nevertheless, challenges persist, particularly regarding the standardization of procedures and potential regulatory hurdles, impacting the speed of introduction for newly developed methodologies in the market.

As the landscape evolves, the potential for robust growth in these segments reflects the overall progress in cancer diagnostics and treatment, reinforcing the significance of the Global Cancer Biopsy Market statistics and data in the forthcoming decade.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Cancer Biopsy Market Application Insights**

The Global Cancer Biopsy Market, particularly within the Application segment, is poised for substantial growth as it is projected to be valued at $11.1 billion in 2024, rising to $20.0 billion in 2035. This market is characterized by a diversification of applications, prominently including Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, and Liver Cancer. Each of these areas plays a crucial role in the overall market dynamics, with Breast and Lung Cancer leading in prevalence, driving demand for precise biopsy techniques.

The significance of cancer biopsy is highlighted by the necessity for accurate diagnosis and treatment planning, which is vital in the management of these cancers, given their high mortality rates.Moreover, ongoing advancements in biopsy technologies and increasing awareness of cancer screening methods are contributing to the market's growth. However, challenges such as rising healthcare costs and procedural risks may hinder market expansion.

Overall, the Global Cancer Biopsy Market data indicate that the rise in cancer incidences and the subsequent need for reliable diagnostics will continue to spur growth across all applications, presenting lucrative opportunities for stakeholders in the Global Cancer Biopsy Market industry.

### **Cancer Biopsy Market Technique Insights**

The Global Cancer Biopsy Market, valued at 11.1 USD Billion in 2024, showcases a diverse and dynamic landscape within the Technique segment, which includes various approaches to tissue sampling. Core **[Needle Biopsy](../../../reports/needle-biopsy-market-3830)** is prominent due to its high accuracy in obtaining sufficient cellular material, making it a preferred choice in many oncology settings. Fine-Needle Aspiration, known for its minimally invasive nature, is also widely utilized, especially for superficial lesions, providing rapid and reliable results. Excisional Biopsy and Incisional Biopsy remain significant as they offer comprehensive tissue analysis, crucial for diagnosing and staging cancer.

As the Global Cancer Biopsy Market revenue is projected to grow, these methodologies are expected to cater to the increasing demand for precise diagnostic techniques. Market trends indicate a shift towards advanced technologies and minimally invasive procedures, driving further growth. However, challenges such as procedural complications and the need for skilled practitioners persist. Nevertheless, opportunities abound in the innovation of biopsy techniques and their integration with imaging technologies, enhancing the overall Global Cancer Biopsy Market industry landscape.

### **Cancer Biopsy Market End User Insights**

The Global Cancer Biopsy Market is poised for significant growth, with a valuation of 11.1 USD Billion in 2024. This market serves multiple End Users, including hospitals, diagnostic laboratories, and cancer research institutes, each playing a vital role in the patient care continuum. Hospitals are essential as they are often the primary point of care for patients requiring biopsies, providing comprehensive services that integrate diagnosis and treatment. Diagnostic laboratories contribute significantly to the accuracy and efficiency of cancer diagnoses, utilizing advanced technologies to analyze biopsy samples.

Meanwhile, cancer research institutes are critical in driving innovation, advancing understanding of cancer biology, and developing new techniques and treatments. The collective contribution of these End Users drives the Global Cancer Biopsy Market revenue, highlighting the interplay of care, diagnostics, and research. Furthermore, trends toward personalized medicine and minimally invasive biopsy techniques underscore opportunities for growth within these segments, while challenges such as regulatory hurdles and high costs may impact market dynamics.Overall, the Global Cancer Biopsy Market segmentation within the End User category reflects a complex and interdependent landscape that is vital for improving cancer patient outcomes.

### **Cancer Biopsy Market Regional Insights**

The Global Cancer Biopsy Market is witnessing considerable growth across various regions, with significant contributions from different areas. In 2024, North America leads with a market valuation of 4.5 USD Billion, and it is expected to reach 8.2 USD Billion by 2035, highlighting its majority holding in the market. Europe follows with a valuation of 3.0 USD Billion in 2024, growing to 5.5 USD Billion in 2035, indicating a significant presence in the Global Cancer Biopsy Market.

The APAC region accounts for a value of 2.5 USD Billion in 2024, projected to expand to 4.5 USD Billion by 2035, reflecting increasing investments and advancements in healthcare.South America and MEA represent smaller shares, with valuations of 0.7 USD Billion and 0.4 USD Billion in 2024, respectively, growing to 1.2 USD Billion and 0.6 USD Billion by 2035. Despite their smaller market sizes, these regions are important emerging markets, offering opportunities for expansion.

Overall, the market growth dynamics are influenced by factors like rising cancer incidence, technological advancements in biopsy procedures, and increasing awareness about early diagnosis across all regions.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Cancer Biopsy Market Key Players and Competitive Insights**

The Global Cancer Biopsy Market has become increasingly competitive as advancements in technology and the growing demand for early cancer diagnosis drive the market forward. This sector includes various minimally invasive techniques and tests that help in the detection and characterization of cancer, leading to better patient outcomes. 

Key players within this market are focusing on developing innovative products that enhance precision and reliability while also reducing the risks associated with traditional biopsy practices. Additionally, strategic collaborations, acquisitions, and mergers are prominent, allowing companies to expand their market reach and enhance their product portfolios to meet the evolving needs of healthcare providers and patients alike.

Abbott Laboratories holds a strong position in the Global Cancer Biopsy Market thanks to its extensive experience in the diagnostics sector and a rich portfolio of innovative products. The company leverages its research and development capabilities to introduce cutting-edge biopsy technologies that cater to various cancer types, enhancing diagnostic accuracy and ensuring timely patient intervention. Abbott Laboratories is recognized for its commitment to high-quality standards and regulatory compliance, which further strengthens its reputation within the market. 

The company’s ability to integrate advanced analytics and AI-driven solutions into its offerings sets it apart from competitors and builds a foundation for long-term growth in the cancer biopsy space.Exact Sciences has emerged as a prominent player in the Global Cancer Biopsy Market through its focus on molecular diagnostics and cancer screening solutions. The company emphasizes the significance of non-invasive testing methods that not only improve patient comfort but also provide comprehensive insights into a patient's cancer status.

Exact Sciences is known for its innovative approaches that incorporate advanced genomic testing, significantly enhancing the accuracy of cancer detection at early stages. Its continuous investment in research and partnerships with healthcare providers allows the company to develop and promote its products effectively, contributing to its growing presence in the competitive landscape of the cancer biopsy market. This proactive strategy showcases Exact Sciences' commitment to transforming cancer diagnostics and improving clinical outcomes for patients worldwide.

### **Key Companies in the Cancer Biopsy Market Include**

- [**Abbott Laboratories**](https://www.molecular.abbott/us/en/offerings/products/oncology)
- Exact Sciences
- Trovagene
- PerkinElmer
- bioMérieux
- Thermo Fisher Scientific
- Roche
- Genomic Health
- Hologic
- Agilent Technologies
- F. HoffmannLa Roche
- NantHealth
- Illumina
- Qiagen
- Cellectis

## Cancer Biopsy Market Industry Developments

- **Q2 2024: Biocept Announces Sale of Laboratory Business to Epic Sciences** Biocept, a molecular diagnostics company specializing in liquid biopsy technology, announced the sale of its laboratory business to Epic Sciences, a leader in cancer diagnostics, in a move to focus on its core intellectual property and assay development.
- **Q2 2024: Guardant Health Receives FDA Approval for Guardant360 CDx Liquid Biopsy Test for Solid Tumors** Guardant Health received FDA approval for its Guardant360 CDx liquid biopsy test, which is designed to detect genomic alterations in solid tumors, expanding its clinical utility for cancer patients.
- **Q2 2024: Exact Sciences Launches Oncotype MAP Pan-Cancer Tissue Test** Exact Sciences announced the launch of its Oncotype MAP Pan-Cancer Tissue Test, a new diagnostic tool that provides comprehensive molecular profiling for multiple cancer types to guide treatment decisions.
- **Q3 2024: Illumina Appoints New CEO Amid Strategic Shift Toward Oncology Diagnostics** Illumina appointed a new CEO to lead the company’s strategic focus on expanding its oncology diagnostics portfolio, including cancer biopsy and liquid biopsy technologies.
- **Q3 2024: Lucence Secures $20 Million Series B Funding to Advance Liquid Biopsy Platform** Lucence, a precision oncology company, raised $20 million in Series B funding to accelerate development and commercialization of its liquid biopsy platform for early cancer detection.
- **Q3 2024: Roche Launches New Digital Pathology Solution for Cancer Biopsy Analysis** Roche introduced a new digital pathology solution designed to enhance the accuracy and efficiency of cancer biopsy analysis, supporting pathologists in diagnostic workflows.
- **Q4 2024: NeoGenomics Expands Laboratory Facility to Increase Cancer Biopsy Testing Capacity** NeoGenomics announced the opening of an expanded laboratory facility to meet growing demand for cancer biopsy testing and molecular diagnostics.
- **Q4 2024: GRAIL Partners with National Cancer Institute for Multi-Center Liquid Biopsy Study** GRAIL entered a partnership with the National Cancer Institute to conduct a multi-center study evaluating the effectiveness of its liquid biopsy technology for early cancer detection.
- **Q1 2025: Bio-Rad Laboratories Acquires Dropworks to Enhance Cancer Biopsy Product Portfolio** Bio-Rad Laboratories completed the acquisition of Dropworks, a company specializing in microfluidic technology, to strengthen its cancer biopsy and liquid biopsy product offerings.
- **Q1 2025: Thermo Fisher Scientific Launches New NGS-Based Cancer Biopsy Assay** Thermo Fisher Scientific launched a new next-generation sequencing (NGS) assay for cancer biopsy samples, enabling more precise genomic profiling for personalized oncology care.
- **Q2 2025: Caris Life Sciences Raises $100 Million in Funding to Expand Molecular Profiling Services** Caris Life Sciences secured $100 million in funding to expand its molecular profiling services, including advanced cancer biopsy diagnostics for personalized medicine.
- **Q2 2025: Qiagen Receives CE Mark for New Liquid Biopsy Kit for Cancer Detection** Qiagen received CE Mark approval for its new liquid biopsy kit, enabling broader access to non-invasive cancer detection solutions in European markets.

## **Cancer Biopsy Market Segmentation Insights**

### **Cancer Biopsy Market Type Outlook**

- Surgical Biopsy
- Needle Biopsy
- Endoscopic Biopsy
- Liquid Biopsy

### **Cancer Biopsy Market Application Outlook**

- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Liver Cancer

### **Cancer Biopsy Market Technique Outlook**

- Core Needle Biopsy
- Fine-Needle Aspiration
- Excisional Biopsy
- Incisional Biopsy

### **Cancer Biopsy Market End User Outlook**

- Hospitals
- Diagnostic Laboratories
- Cancer Research Institutes

### **Cancer Biopsy Market Regional Outlook**

- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa

## Market Drivers

### Rising Incidence of Cancer

The increasing incidence of cancer worldwide is a primary driver for the Cancer Biopsy Market. According to recent statistics, cancer cases are projected to rise significantly, with estimates suggesting that by 2040, the number of new cancer cases could reach 27.5 million annually. This alarming trend necessitates advanced diagnostic tools, including biopsies, to ensure timely and accurate cancer detection. As healthcare systems strive to improve patient outcomes, the demand for various biopsy techniques, such as needle biopsies and surgical biopsies, is likely to surge. Consequently, the Cancer Biopsy Market is expected to expand as healthcare providers invest in innovative biopsy technologies to meet the growing need for effective cancer diagnosis.

### Growth in Personalized Medicine

The shift towards personalized medicine is reshaping the Cancer Biopsy Market. Personalized medicine emphasizes tailored treatment plans based on individual patient profiles, which often necessitates precise diagnostic information obtained through biopsies. As targeted therapies become more prevalent, the need for accurate tumor characterization through biopsy samples is paramount. This trend is reflected in the increasing use of molecular profiling techniques, which rely on biopsy specimens to identify specific genetic mutations and inform treatment decisions. Consequently, the Cancer Biopsy Market is likely to experience growth as healthcare providers invest in advanced biopsy technologies that facilitate personalized treatment approaches, ultimately improving patient outcomes.

### Increasing Awareness and Screening Programs

The growing awareness of cancer and the importance of early detection is significantly influencing the Cancer Biopsy Market. Public health campaigns and educational initiatives are encouraging individuals to participate in regular screening programs, which often include biopsy procedures for definitive diagnosis. For instance, [breast cancer](https://www.marketresearchfuture.com/reports/global-breast-cancer-market-1379) screening programs have led to an increase in the number of biopsies performed, as early detection is crucial for effective treatment. This heightened awareness is expected to drive demand for various biopsy methods, including fine-needle aspiration and core needle biopsies. As more individuals seek preventive care, the Cancer Biopsy Market is poised for substantial growth, with healthcare providers adapting to meet the rising demand for diagnostic services.

### Technological Innovations in Biopsy Techniques

Technological advancements in biopsy techniques are transforming the Cancer Biopsy Market. Innovations such as liquid biopsies, which analyze circulating tumor DNA, are gaining traction due to their non-invasive nature and ability to provide real-time insights into tumor dynamics. Furthermore, advancements in imaging technologies, such as MRI and CT scans, enhance the precision of biopsy procedures, thereby improving diagnostic accuracy. The integration of artificial intelligence in pathology is also streamlining the analysis of biopsy samples, leading to faster and more reliable results. As these technologies continue to evolve, they are likely to drive growth in the Cancer Biopsy Market, attracting investments and fostering research initiatives aimed at improving cancer diagnostics.

### Regulatory Support and Funding for Cancer Research

Regulatory support and increased funding for cancer research are pivotal drivers of the Cancer Biopsy Market. Governments and health organizations are recognizing the critical need for innovative cancer diagnostics and are allocating resources to support research initiatives. This funding often translates into the development of new biopsy techniques and technologies, enhancing the overall landscape of cancer diagnostics. Additionally, regulatory bodies are streamlining approval processes for novel biopsy methods, facilitating quicker access to advanced diagnostic tools. As a result, the Cancer Biopsy Market is likely to benefit from these supportive measures, fostering innovation and improving the availability of effective biopsy solutions for cancer patients.

## Future Outlook

The Cancer Biopsy Market is projected to grow at a 5.49% CAGR from 2025 to 2035, driven by technological advancements, increasing cancer prevalence, and rising demand for early diagnosis.

**New opportunities:**

- Development of AI-driven diagnostic tools for enhanced accuracy
- 
- Expansion of minimally invasive biopsy techniques in outpatient settings
- Partnerships with telehealth platforms for remote biopsy consultations

By 2035, the Cancer Biopsy Market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Type: Surgical Biopsy (Largest) vs. Liquid Biopsy (Fastest-Growing)

In the Cancer Biopsy Market, the surgical biopsy segment holds the largest market share, driven by its established presence and trust among healthcare providers. Needle biopsies also contribute significantly, valued for their precision and less invasive nature. Endoscopic biopsies, while less common, play a crucial role in specific cancer types, whereas liquid biopsies are rapidly gaining traction. This innovation allows for real-time monitoring and early detection, carving a niche in personalized medicine. As the landscape of cancer diagnostics evolves, research and technological advancements fuel the growth of the [liquid biopsy](https://www.marketresearchfuture.com/reports/liquid-biopsy-market-710) segment. Increasing demand for minimally invasive alternatives and the need for timely diagnosis highlight the potential for this segment to grow exponentially. The ongoing integration of liquid biopsies into routine clinical practice offers promising prospects for the future, signifying a shift towards more patient-friendly methodologies in cancer management.

Surgical Biopsy (Dominant) vs. Liquid Biopsy (Emerging)

The surgical biopsy segment is characterized by its robustness and reliability, often viewed as the gold standard for cancer diagnosis. Typically performed in a surgical setting, this method allows for the comprehensive collection of tissue samples, providing detailed histological information critical for accurate diagnosis. However, the liquid biopsy segment is emerging as a groundbreaking approach, utilizing blood samples to detect cancer biomarkers with minimally invasive procedures. This innovative technology appeals to both patients and practitioners due to its convenience and potential for real-time monitoring of disease progression. Liquid biopsies hold the promise of improving personalized treatment plans, distinguishing themselves as a transformative force in the Cancer Biopsy Market.

### By Application: Breast Cancer (Largest) vs. Lung Cancer (Fastest-Growing)

In the Cancer Biopsy Market, Breast Cancer holds the largest share, reflecting the high prevalence of this malignancy and the increased screening efforts focusing on early detection. Lung Cancer follows as a significant segment, driven by rising awareness and improved diagnostic technology. Colorectal Cancer, Prostate Cancer, and Liver Cancer also contribute, but they occupy smaller shares relative to the leading segments. The market's expansive growth illustrates the critical role of diagnostics in cancer treatment alternatives, with emphasis placed on innovative biopsy techniques. Growth trends indicate that while Breast Cancer remains the dominant application, Lung Cancer is rapidly evolving as the fastest-growing segment due to advancements in targeted therapies and an increase in the number of patients seeking diagnostic confirmations. Factors such as enhanced imaging techniques, governmental health initiatives, and a greater emphasis on personalized medicine lead to robust growth across all applications. Continuous research into less invasive biopsy methods presents significant opportunities for expansion in the Cancer Biopsy Market across diverse cancer types.

Breast Cancer: Dominant vs. Lung Cancer: Emerging

Breast Cancer as a dominant segment in the Cancer Biopsy Market showcases the ongoing necessity for precise diagnostic tools due to its high incidence rates. This application benefits from extensive research funding, the availability of advanced biopsy techniques, and a well-established network of screening programs aimed at early detection. In contrast, Lung Cancer, identified as an emerging segment, highlights the increasing shift towards minimally invasive biopsy procedures and the development of targeted therapies. The rising global burden of lung cancer incidence necessitates novel diagnostic strategies, propelling growth in biopsy technologies. The focus on lung cancer promotes innovation, particularly in liquid biopsies and other non-invasive techniques, making this segment attractive for future investments in research and development.

### By Technique: Core Needle Biopsy (Largest) vs. Fine-Needle Aspiration (Fastest-Growing)

The Cancer Biopsy Market showcases a diverse range of techniques, each contributing to overall market dynamics. Among these, Core Needle Biopsy holds the significant share, leveraging its efficacy in obtaining larger tissue samples for accurate diagnosis. Fine-Needle Aspiration, while smaller in market share compared to Core Needle Biopsy, is rapidly gaining traction due to its minimally invasive approach and less patient discomfort. As the market evolves, growth drivers include technological advancements leading to improved accuracy and reduced procedural risks. The rise in cancer incidence, coupled with an increasing emphasis on early diagnosis, propels the demand for these biopsy techniques. Additionally, the integration of imaging technologies with biopsy methods is enhancing their adoption across healthcare settings.

Technique: Core Needle Biopsy (Dominant) vs. Fine-Needle Aspiration (Emerging)

Core Needle Biopsy is positioned as the dominant technique within the Cancer Biopsy Market, renowned for its ability to extract larger tissue samples, thereby facilitating accurate histopathological assessment. Its effectiveness has made it a go-to choice for diagnosing various cancers, especially those in challenging anatomical locations. On the other hand, Fine-Needle Aspiration is emerging as a preferred choice due to its minimal invasiveness and lower complication rates. Patients favor this technique for its associated comfort and quicker recovery time, which aligns with modern healthcare's focus on patient-centric approaches. Together, these techniques complement each other, offering distinct advantages that cater to diverse clinical requirements.

### By End User: Hospitals (Largest) vs. Diagnostic Laboratories (Fastest-Growing)

The Cancer Biopsy Market exhibits a distinct distribution of market share among its end-user segments. Hospitals hold the largest share, largely due to their comprehensive facilities and ability to conduct a wide range of diagnostic procedures. They serve as primary healthcare providers, which results in a high volume of biopsies being performed for cancer diagnosis and management. In contrast, diagnostic laboratories are rapidly emerging as critical players, reflecting a shift towards specialized testing and the increasing reliance on accurate and prompt results.

End User: Hospitals (Dominant) vs. Diagnostic Laboratories (Emerging)

Hospitals represent the dominant force within the Cancer Biopsy Market, offering extensive services and resources to manage cancer patients effectively. Their ability to integrate biopsy services with other treatments enhances patient care and contributes to their significant market position. Diagnostic laboratories, on the other hand, are seen as an emerging segment, characterized by their focus on specialized cancer testing. With advancements in technology and increased demand for precision medicine, they offer rapid and accurate testing, propelling their growth in the market as healthcare providers look for reliable partners in cancer diagnostics. This dynamic places diagnostic laboratories on a promising trajectory as they complement the traditional role of hospitals.

## Regional Market Share Analysis

The Global Cancer Biopsy Market is witnessing considerable growth across various regions, with significant contributions from different areas. In 2024, North America leads with a market valuation of 4.5 USD Billion, and it is expected to reach 8.2 USD Billion by 2035, highlighting its majority holding in the market. Europe follows with a valuation of 3.0 USD Billion in 2024, growing to 5.5 USD Billion in 2035, indicating a significant presence in the Global Cancer Biopsy Market.

The APAC region accounts for a value of 2.5 USD Billion in 2024, projected to expand to 4.5 USD Billion by 2035, reflecting increasing investments and advancements in healthcare.South America and MEA represent smaller shares, with valuations of 0.7 USD Billion and 0.4 USD Billion in 2024, respectively, growing to 1.2 USD Billion and 0.6 USD Billion by 2035. Despite their smaller market sizes, these regions are important emerging markets, offering opportunities for expansion.

Overall, the market growth dynamics are influenced by factors like rising cancer incidence, technological advancements in biopsy procedures, and increasing awareness about early diagnosis across all regions.

## Competitive Benchmarking

The Global Cancer Biopsy Market has become increasingly competitive as advancements in technology and the growing demand for early cancer diagnosis drive the market forward. This sector includes various minimally invasive techniques and tests that help in the detection and characterization of cancer, leading to better patient outcomes. Key players within this market are focusing on developing innovative products that enhance precision and reliability while also reducing the risks associated with traditional biopsy practices. Additionally, strategic collaborations, acquisitions, and mergers are prominent, allowing companies to expand their market reach and enhance their product portfolios to meet the evolving needs of healthcare providers and patients alike.Abbott Laboratories holds a strong position in the Global Cancer Biopsy Market thanks to its extensive experience in the diagnostics sector and a rich portfolio of innovative products. The company leverages its research and development capabilities to introduce cutting-edge biopsy technologies that cater to various cancer types, enhancing diagnostic accuracy and ensuring timely patient intervention. Abbott Laboratories is recognized for its commitment to high-quality standards and regulatory compliance, which further strengthens its reputation within the market. The company’s ability to integrate advanced analytics and AI-driven solutions into its offerings sets it apart from competitors and builds a foundation for long-term growth in the cancer biopsy space.Exact Sciences has emerged as a prominent player in the Global Cancer Biopsy Market through its focus on molecular diagnostics and cancer screening solutions. The company emphasizes the significance of non-invasive testing methods that not only improve patient comfort but also provide comprehensive insights into a patient's cancer status.Exact Sciences is known for its innovative approaches that incorporate advanced genomic testing, significantly enhancing the accuracy of cancer detection at early stages. Its continuous investment in research and partnerships with healthcare providers allows the company to develop and promote its products effectively, contributing to its growing presence in the competitive landscape of the cancer biopsy market. This proactive strategy showcases Exact Sciences' commitment to transforming cancer diagnostics and improving clinical outcomes for patients worldwide.

## Recent News & Developments

- **Q2 2024: Biocept Announces Sale of Laboratory Business to Epic Sciences** Biocept, a molecular diagnostics company specializing in liquid biopsy technology, announced the sale of its laboratory business to Epic Sciences, a leader in cancer diagnostics, in a move to focus on its core intellectual property and assay development.
- **Q2 2024: Guardant Health Receives FDA Approval for Guardant360 CDx Liquid Biopsy Test for Solid Tumors** Guardant Health received FDA approval for its Guardant360 CDx liquid biopsy test, which is designed to detect genomic alterations in solid tumors, expanding its clinical utility for cancer patients.
- **Q2 2024: Exact Sciences Launches Oncotype MAP Pan-Cancer Tissue Test** Exact Sciences announced the launch of its Oncotype MAP Pan-Cancer Tissue Test, a new diagnostic tool that provides comprehensive molecular profiling for multiple cancer types to guide treatment decisions.
- **Q3 2024: Illumina Appoints New CEO Amid Strategic Shift Toward Oncology Diagnostics** Illumina appointed a new CEO to lead the company’s strategic focus on expanding its oncology diagnostics portfolio, including cancer biopsy and liquid biopsy technologies.
- **Q3 2024: Lucence Secures $20 Million Series B Funding to Advance Liquid Biopsy Platform** Lucence, a precision oncology company, raised $20 million in Series B funding to accelerate development and commercialization of its liquid biopsy platform for early cancer detection.
- **Q3 2024: Roche Launches New Digital Pathology Solution for Cancer Biopsy Market Analysis** Roche introduced a new digital pathology solution designed to enhance the accuracy and efficiency of cancer biopsy analysis, supporting pathologists in diagnostic workflows.
- **Q4 2024: NeoGenomics Expands Laboratory Facility to Increase Cancer Biopsy Market Testing Capacity** NeoGenomics announced the opening of an expanded laboratory facility to meet growing demand for cancer biopsy testing and molecular diagnostics.
- **Q4 2024: GRAIL Partners with National Cancer Institute for Multi-Center Liquid Biopsy Study** GRAIL entered a partnership with the National Cancer Institute to conduct a multi-center study evaluating the effectiveness of its liquid biopsy technology for early cancer detection.
- **Q1 2025: Bio-Rad Laboratories Acquires Dropworks to Enhance Cancer Biopsy Market Product Portfolio** Bio-Rad Laboratories completed the acquisition of Dropworks, a company specializing in microfluidic technology, to strengthen its cancer biopsy and liquid biopsy product offerings.
- **Q1 2025: Thermo Fisher Scientific Launches New NGS-Based Cancer Biopsy Market Assay** Thermo Fisher Scientific launched a new next-generation sequencing (NGS) assay for cancer biopsy samples, enabling more precise genomic profiling for personalized oncology care.
- **Q2 2025: Caris Life Sciences Raises $100 Million in Funding to Expand Molecular Profiling Services** Caris Life Sciences secured $100 million in funding to expand its molecular profiling services, including advanced cancer biopsy diagnostics for personalized medicine.
- **Q2 2025: Qiagen Receives CE Mark for New Liquid Biopsy Kit for Cancer Detection** Qiagen received CE Mark approval for its new liquid biopsy kit, enabling broader access to non-invasive cancer detection solutions in European markets.

## Report Scope

| MARKET SIZE 2024 | 11.11(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 11.72(USD Billion) |
| MARKET SIZE 2035 | 20.0(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.49% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Roche (CH), Thermo Fisher Scientific (US), Abbott Laboratories (US), Becton Dickinson and Company (US), Hologic (US), Siemens Healthineers (DE), Philips (NL), Agilent Technologies (US), Exact Sciences Corporation (US) |
| Segments Covered | Types, Applications, Technique, End Users, Regional |
| Key Market Opportunities | Advancements in liquid biopsy technologies enhance early cancer detection and patient monitoring in the Cancer Biopsy Market. |
| Key Market Dynamics | Technological advancements and regulatory changes drive innovation and competition in the Cancer Biopsy Market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Cancer Biopsy Market as of 2024?**
A: The Cancer Biopsy Market was valued at 11.11 USD Billion in 2024.

**Q: What is the projected market size for the Cancer Biopsy Market by 2035?**
A: The market is projected to reach 20.0 USD Billion by 2035.

**Q: What is the expected CAGR for the Cancer Biopsy Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Cancer Biopsy Market during 2025 - 2035 is 5.49%.

**Q: Which segment of the Cancer Biopsy Market is expected to grow the most by 2035?**
A: The Liquid Biopsy segment, projected to grow from 3.34 to 6.67 USD Billion, appears to show significant growth potential.

**Q: What are the key applications driving the Cancer Biopsy Market?**
A: Key applications include Breast Cancer, Lung Cancer, and Liver Cancer, with valuations expected to reach 4.5, 3.5, and 6.5 USD Billion respectively by 2035.

**Q: Which companies are leading the Cancer Biopsy Market?**
A: Key players in the market include Roche, Thermo Fisher Scientific, and Abbott Laboratories, among others.

**Q: What is the expected growth in the Surgical Biopsy segment by 2035?**
A: The Surgical Biopsy segment is projected to grow from 3.33 to 5.83 USD Billion by 2035.

**Q: How do end-user segments contribute to the Cancer Biopsy Market?**
A: Hospitals, Diagnostic Laboratories, and Cancer Research Institutes are expected to drive growth, with hospitals projected to reach 8.0 USD Billion by 2035.

**Q: What techniques are anticipated to dominate the Cancer Biopsy Market?**
A: Core Needle Biopsy and Fine-Needle Aspiration are expected to dominate, with projected valuations of 4.5 and 5.5 USD Billion respectively by 2035.

**Q: What trends are influencing the Cancer Biopsy Market in 2025?**
A: Trends include advancements in biopsy techniques and increasing demand for early cancer detection, which may drive market growth.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/cancer-biopsy-market-42309*